This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Netherlands
AIMM Therapeutics is a clinical stage antibody discovery company focused on Infectious- and inflammatory-Diseases, and Oncology. AIMM?s approach is to immortalize and capture the entire B cell repertoires from human donors or from vaccinated animals. The antigen specific and/or functionally active mAbs and associated B cells are then separated from the repertoire. The rarest of B cells are captured, cloned, and their antibodies identified in as little as three weeks. AIMM initially validated this platform in infectious diseases including Influenza, CMV, HCV, MRSA, C.Diff, and RSV. AIMM has executed three antibody licensing agreements with major pharmaceutical companies including Genentech/Roche, Medimmune/AZ, and Crucell/J&J. One of AIMM?s antibodies is being studies in two Phase II trials and a second should enter the clinic in 2014. The company current research focus includes Oncology and Respiratory Diseases. By leveraging its close relationship with the National Cancer Institute (NKI) and the Academic Medical Center (AMC), AIMM is alerted to patients who show a unique response to a disease of interest. Blood or tissue sample are then obtained and the clinically relevant antibodies and B cells identified. In the case of AML and Melanoma, AIMM has identified human antibodies that are selective for and active in disease specific models. The immortalized B cells may be further affinity matured without the need for resource intensive molecular engineering. AIMM has shown that both affinity and stability may be optimized through its unique in situ process.The company has also validated this approach in non-human animals, both wild-type and genetically modified (mouse and rabbit). AIMM has shown that it can improve the efficiency of the hybridoma process by 3 to 4 orders of magnitude. Today species such as the rabbit, which is well recognized for its ability to produce extremely high affinity antibodies, may now be used in therapeutics and diagnostic applications where monoclonal antibodies are required.
Alloksys Life Sciences BV is a biopharmaceutical company active in the R&D of therapeutic proteins for the treatment of both acute inflammatory clinical conditions and diseases. Leading product is RESCAP, which has progressed to clinical phase 3a as therapeutic intervention for the prevention and treatment of ischemic injury/hypoxia mediated injury following invasive surgery. As suggested in peer reviewed publications by third parties these (inflammatory) complications have long-term adverse effects on morbidity and survival and will significantly affect health economics. From this RESCAP intervention will benefit not only the affected patients.
AM-Pharma is a biopharmaceutical company, engaged in the development of proprietary recombinant human alkaline phosphatase therapeutics for unmet needs in severe inflammatory diseases. The company is developing recombinant human Alkaline Phosphatase for treatment of Acute Kidney Injury (iv) and Ulcerative Colitis (oral).
Amarna Therapeutics is a biotechnology company that developed a novel viral gene delivery vector platform denoted SVac with unique properties to generate the next generation of medicines to treat the major disease of our time, such as infectious diseases, autoimmune diseases and cancer.
Angita Pharmaceuticals B.V. (Angita) is an early stage Pharmaceutical Company, with a focus on drug discovery for treatment of diseases of the Central Nervous System (CNS). Angita has a publicly announced pipeline of 6 projects ranging from very early ?Target validation? stage to a project for symptomatic relief and cognitive enhancement in Parkinson?s Disease which is close to entering formal pre-clinical development studies.
APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. Company has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1.
Arcarios is a drug development company dedicated to the discovery and development of innovative products in the field of bone and joint diseases such as osteoporosis and osteoarthritis. Company's lead programs are ARC-118 for osteoarthritis and ARC-205 for bone diseases.
arGEN-X is a therapeutic antibody discovery and development company with unique strengths in tackling complex disease targets beyond the reach of traditional antibody platforms.
Through its powerful suite of antibody technologies, arGEN-X creates highly differentiated candidates with enormous development potential as best- and first-in-class products.
Through its powerful suite of antibody technologies, arGEN-X creates highly differentiated candidates with enormous development potential as best- and first-in-class products.
Arthrogen BV is a biopharmaceutical company focusing on the development of local gene therapy for rheumatic diseases using viral mediated gene transfer. Company's lead product ART-I02 is a recombinant adeno-associated virus (rAAV) type 5 vector genetically designed to encode human interferon-? (hIFN?).
Biocult b.v. provides contract manufacturing services for monoclonal antibodies, establishing of cell banks and the manufacture of MAB for clinical (Phase I) studies according to GMP guidelines.
BiOrion is a Dutch biopharmaceutical company developing targeted peptide-drugs for life-threatening and devastating fibroblast-associated diseases, such as renal, pulmonary and hepatic fibrosis and stroma-driven tumors e.g. pancreatic cancer and breast cancer.
Brant is a private European based company which aims to transform early stage projects into products of high value. Brant's mission is to search, acquire, develop and license out projects of high potential value in areas directly matching key experience and success of the company and its above cited internal partners.